Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
NCT05850520Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2023
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 27
01
Overview
A Phase 3 trial of aflibercept in retinal vein occlusion (RVO), sponsored by Bayer. Started May 2023; status: completed.
02
Drugs
aflibercept
03
Conditions
retinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT05850520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850520.